medigraphic.com

2018, Number 4

<< Back Next >>

Rev Hosp Jua Mex 2018; 85 (4)

Association between climacteric and depressive symptoms in Mexican women

Macías-Cortés EC, Llanes-González L

Language: Spanish
References: 29
Page: 185-194
PDF size: 246.61 Kb.


ABSTRACT

Introduction: Climacteric is a period of hormonal changes associated with depression. Objective: To determine the magnitude of the association between climacteric and depressive symptoms in Mexican women. Material and methods: A cross-sectional study was conducted at the outpatient service of Hospital Juarez de Mexico, between March 2012 and December 2013. Five hundred and thirty four women, 40 to 65 years were included. Severity of depressive symptoms was assessed using two scales (Hamilton scale [HS] and Beck depression inventory [BDI]) and climacteric symptoms using Greene scale (GS). Association between climacteric and depressive symptoms was analyzed using logistic regression. Results: Women with moderate to severe climacteric symptoms were up to 7.82 (5.17-11.81) and 8.12 (5.51-11.98) times more likely to have moderate depressive symptoms using HS and BDI respectively. Normal or mild climacteric symptoms are protective factors for moderate to severe depressive symptoms [HS: OR (IC 95%) 0.196 (0.123-0-134), p = 0.000 and BDI: OR 0.172 (0.110-0.271), p = 0.000]. Conclusion: Based on the significant association between climacteric symptoms and severity of depressive symptoms, it is mandatory to include a comprehensive approach during transition to menopause, to early detect and treat both depression and climacteric symptoms.


REFERENCES

  1. Benjet C, Borges G, Medina-Mora ME, Fleiz-Bautista C, Zambrano-Ruiz J. La depresión con inicio temprano: prevalencia, curso natural y latencia para buscar tratamiento. Salud Publica Mex 2004; 46(5): 417-24.

  2. Medina-Mora ME, Borges G, Benjet C, Lara C, Berglund P. Psychiatry disorders in Mexico: lifetime prevalence in a nationally representative sample. BJP 2007; 190: 521-8.

  3. Capote Bueno MI, Segredo Pérez AM, Gómez Zayas O. Climaterio y menopausia. Rev Cubana Med Gen Integr 2011; 27(4): 543-57.

  4. CONAPO. Secretaría de Gobernación. Dinámica demográfica 1990-2010 y proyecciones de población 2010-2030. http://www.conapo.gob.mx/work/models/CONAPO/Proyecciones/Cuadernos/15_Cuadernillo_Mexico.pdf

  5. Bassol M. La edad de la menopausia en México. Revista de Endocrinología y Nutrición 2006; 14(2): 133-6.

  6. Jansen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and metabolic syndrome. Arch Intern Med 2008; 168(14): 1568-75.

  7. Nelson HD. Menopause. Lancet 2008; 371: 760-70.

  8. Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004; 61: 62-70.

  9. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition. The Harvard study of moods and cycles. Arch Gen Psychiatry 2006; 63: 385-90.

  10. Worsley R, Bell R, Kulkarni J, Davis SR. The association between vasomotor symptoms and depression during perimenopause: a systematic review. Maturitas 2014; 77: 111-7.

  11. Natari RB, Clavarino AM, McGuire TM, Dingle KD, Hollingworth SA. The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies. Menopause 2018; 25(1): 109-20.

  12. Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007; 196: 97-106.

  13. Horna-López A, Romero-Gutiérrez G, Horna-Quiroz M, Malacara-Hernández JM, Pérez-Luque EL. Perfil sintomático en mujeres peri y posmenopáusicas. Ginecol Obstet Mex 2006; 74: 312-16.

  14. Hernández-Valencia M, Córdova-Pérez N, Basurto L et al. Frecuencia de los síntomas del síndrome climatérico. Ginecol Obstet Mex 2010; 78 (4): 232-7.

  15. Macías-Cortés EC, Aguilar-Faisal L, Asbun-Bojalil J. Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial. Trials 2013; 14: 105.

  16. Macías-Cortés EC, Llanes-González L, Aguilar-Faisal L, Asbun-Bojalil J. Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP Study): a randomized, double-dummy, double-blind, placebo-controlled trial. PLoS One. 2015; 10(3): e0118440. doi: 10.1371/journal.pone.0118440.

  17. Soules MR, Sherman S, Parrot E, Rebar R, Santoro N, Utian W, Woods N. Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gender-Based Med 2001; 10: 843-48.

  18. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-96.

  19. Ramos-Brieva JC. Validación de la versión castellana de la escala de Hamilton para la depresión. Actas Luso-Esp Neurol Psiquiatr 1986; 14: 324-34.

  20. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care –NICE guidance. 2004.

  21. Beck AT, Steer RA, Garbin MG, Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988; 8: 77-100.

  22. Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 29: 25-31.

  23. Berenzon S, Lara MA, Robles R, Medina-Mora ME. Depresión: estado del conocimiento y la necesidad de políticas públicas y planes de acción en México. Salud Publica Mex 2013; 55: 74-80.

  24. González-Pier E, Gutiérrez-Delgado C, Stevens G, Barraza-Llorens M, Porras-Condey R, Carvalho N et al. Definición de prioridades para las intervenciones de salud en el Sistema de Protección Social en Salud de México. Salud Publica Mex 2007; 49(Supl. I): 537-52.

  25. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004; 61: 62-70.

  26. Wise PM, Smith MJ, Dubal DB. Neuroendocrine influences and repercussions of the menopause. Endoc Rev 1999; 20: 243-8.

  27. Goldbacher EM, Bromberger J, Matthews KA. Lifetime history of major depression predicts the development of the metabolic syndrome in middle-aged women. Psychosom Med 2009; 7 (3): 266-72.

  28. Muka T, Oliver-Williams C, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One 2016; 11: e0157417.

  29. Rafful C, Medina-Mora ME, Borges G, Benjet C, Orozco R. Depression, gender and the treatment gap in Mexico. J Affect Disord 2012; 138(35): 1-11.




2020     |     www.medigraphic.com